CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 104ef0f2-3c97-42e2-8507-9b6ddf7ebf49
exploratory
The evidence profile contains no sources classified primarily as direct clinical evidence, 8 adjacent clinical sources, and 3 mechanistic or model-system sources, with 17 cross-study disagreements across the evidence base.
Contradiction: none
Sources: 5
exploratoryPositive study-level signals are summarized in the deficiency prevalence outcome class, null signals in the deficiency prevalence, contextual adjacent evidence and immune outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.
Contradiction: none
Sources: 5
exploratoryThe conclusion is that glynac should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Contradiction: none
Sources: 5
exploratoryThis manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-glynac-v06-DAILY-2026-06-01T01-39-40Z`.
Contradiction: none
Sources: 5
exploratoryThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.
Contradiction: none
Sources: 5
exploratoryPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.
Contradiction: none
Sources: 5
exploratoryEvidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune, immune and inflammation, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.
Contradiction: none
Sources: 5
exploratorySource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.
Contradiction: none
Sources: 5
exploratoryOutcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.
Contradiction: none
Sources: 5
exploratory| Contextual Adjacent Evidence | n=3; claims=18 | no extracted directional signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratoryThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.
Contradiction: none
Sources: 5
exploratory5 included sources were assigned to this outcome class. Directional coding: null=3, positive=1, unclear=1. Directness coding: indirect=2, mechanistic=2, review=1.
Contradiction: none
Sources: 5
exploratory3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=2, review=1.
Contradiction: none
Sources: 5
exploratory3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: review=3.
Contradiction: none
Sources: 5
exploratoryThis synthesis maps 16 included sources on glynac across 6 outcome classes and 17 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Contradiction: none
Sources: 5
exploratoryAcross 16 curated reference papers, the evidence base for glynac shows a context-dependent profile. Positive signals appear in: deficiency prevalence. Null findings dominate: deficiency prevalence, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The glynac anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.
Contradiction: none
Sources: 5
exploratoryPrior reviews in the corpus (CORRECTING 2019, CORRECTING 2019b, Sekhar 2021) emphasize convergent signals on glynac. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.
Contradiction: none
Sources: 5
exploratory| deficiency prevalence | 0 | 5 | null, positive, unclear | direct clinical gap |
Contradiction: none
Sources: 5
exploratory| P1 | immune: direct clinical gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
Contradiction: none
Sources: 5
exploratory| P2 | contextual adjacent evidence: direct clinical gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
Contradiction: none
Sources: 5
exploratory| P3 | deficiency prevalence: direct clinical gap | 0 direct and 5 indirect sources; direction profile: null, positive, unclear |
Contradiction: none
Sources: 5
exploratoryThe next high-yield study for glynac should target the **immune** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.
Contradiction: none
Sources: 5
exploratoryThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.
Contradiction: none
Sources: 5
exploratoryKumar 2021b; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=deficiency prevalence; direction=null.
Contradiction: none
Sources: 5
exploratoryAdditional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Wang 2026 vs Sekhar 2022; Wang 2026 (unclear) vs Sekhar 2022 (mixed) on dosing pharmacokinetics
Contradiction: none
Sources: 5
exploratorySeverity 3 null vs positive: Sekhar 2021 vs Angelini 2024; Sekhar 2021 (unclear) vs Angelini 2024 (null) on contextual other
Contradiction: none
Sources: 5
exploratorySeverity 3 null vs positive: Sekhar 2021 vs Gut 2021; Sekhar 2021 (unclear) vs Gut 2021 (null) on contextual other
Contradiction: none
Sources: 5
exploratorySeverity 3 null vs positive: CORRECTING 2019 vs Sekhar 2022b; CORRECTING 2019 (unclear) vs Sekhar 2022b (null) on immune
Contradiction: none
Sources: 5
exploratorySeverity 3 null vs positive: CORRECTING 2019b vs Sekhar 2022b; CORRECTING 2019b (unclear) vs Sekhar 2022b (null) on immune
Contradiction: none
Sources: 5
exploratorySeverity 3 null vs positive: Kumar 2023 vs Kumar 2021; Kumar 2023 (null) vs Kumar 2021 (unclear) on deficiency prevalence
Contradiction: none
Sources: 5